Published on 08 April 2019
Ingredia launches Pep2dia®, its innovative bioactive to delay the onset of type 2 diabetes.
Pep2Dia® is the result of extensive research and collaboration between Ingredia’s scientists and LIENSs-CNRS La Rochelle University in France. Pep2Dia® has proven efficacy on glycaemia after meals. Pre-clinical and clinical studies support Pep2Dia®’s action to reduce postprandial glycaemia with a significative effect versus the placebo.
